The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated
